Author Archives: admin

5934

primo steroid

Nausea, mucosal erosions of the gastrointestinal tract, confusion, dizziness, unconsciousness, hallucinations, tremors and seizures, prolongation of the interval primo steroid. Treatment: symptomatic; monitoring parameters; appointment of antacids. No specific antidote.

Interaction with other drugs

Salts of iron, zinc, antacids, salts containing magnesium or aluminum, didanosine (Only those preparations of didanosine which comprise as auxiliary substances magnesium and aluminum) significantly reduce the absorption of levofloxacin while receiving.
In an application of levofloxacin and iron salts, zinc salts, antacids containing magnesium or aluminum, didanosine recommended to assign the last 2 hours after administration of levofloxacin (or 2 hours before receiving levofloxacin).
calcium salts have little effect on the oral absorption of levofloxacin. Sucralfate significantly reduces the bioavailability of levofloxacin. With simultaneous use of levofloxacin and sucralfate are encouraged to nominate the last 2 hours after receiving levofloxacin. There were no pharmacokinetic interactions between levofloxacin and theophylline. However, the concomitant use of quinolones with theophylline, primo steroid and other drugs that reduce the seizure threshold may be lowered seizure threshold. in the presence of fenbufen levofloxacin concentration of about 13% higher than when used as monotherapy.when concomitant use levofloxacin  increased by 33%. In an application with indirect anticoagulants, coumarin derivatives (eg., Warfarin), there is an increase of indicators of coagulation (prothrombin time / international normalized ratio (INR)) and / or bleeding. Cimetidine and probenecid, as a result of blocking the renal tubular secretion, reduce the renal clearance of levofloxacin 24% and 34%, respectively, so levofloxacin should be used with caution in conjunction with drugs that affect the tubular secretion (such as probenecid and cimetidine), especially in patients with impaired renal function. levofloxacin may lengthen the interval , so be careful when the simultaneous use of antiarrhythmic drugs class IA and III, tricyclic antidepressants, macrolides and neuroleptics.Glucocorticoids increase the risk of tendon rupture. no clinically meaningful effect on the pharmacokinetics of levofloxacin had no concomitant use of calcium carbonate, glibenclamide, ranitidine, digoxin.

 

special instructions

The prevalence of acquired resistance strains of pathogens may vary depending on geographic region and over time. In connection with this required information on microbial resistance to the drug in a particular country. For treatment of severe infections or when treatment failure should be set microbiological diagnosis with the release of the pathogen and the determination of its sensitivity to levofloxacin.
There is a high probability that the methicillin-resistant staphylococcus aureus would be resistant to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of established or suspected infections causedaureus, if laboratory tests have not confirmed the sensitivity of the organism to levofloxacin. Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (angioedema, anaphylactic shock), even when primo steroid using the initial . Patients should stop taking the drug and consult a doctor.
When receiving levofloxacin observed cases of severe bullous skin reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis. In the case of any reaction on the part of the skin and the mucous membranes of the patient should seek medical advice immediately and continue treatment to his advice.
Reported cases of hepatic necrosis, including the development of fatal liver failure in the application of levofloxacin, primarily in patients with severe major diseases, such as sepsis (see. “Side effects” section). Patients should be warned about the need to stop treatment and urgent referral to a doctor in case of symptoms and liver disease symptoms such as anorexia, jaundice, dark urine, itching, and abdominal pain.
Should be taken 2 hours before or 2 hours after administration of iron salts, zinc salts, sucralfate or didanosine (only ddI formulations, which contain as excipients magnesium and aluminum), because there may be a decrease in its absorption.
patients concurrently taking indirect anticoagulants, coumarin derivatives, it is necessary to control parameters blood clotting.
In rare cases, observed during treatment with quinolones, tendinitis can lead to rupture of ligaments, especially the Achilles tendon. This side effect is apparent within 48 hours after initiation of therapy. For the elderly and patients taking steroids, there is an increased risk of developing tendinitis. Therefore, during treatment with levofloxacin should be closely monitored the status of such patients.
If there is a suspicion of tendonitis (to inform patients about its symptoms), reception primo steroid is necessary to stop and start the appropriate treatment immediately (eg., Immobilization).
Diarrhoea (especially in cases of severe resistant and / or mixed with blood) during or after reception  may be a symptom of disease caused by Clostridium difficile, the most severe form of which is pseudomembranous colitis. If there is a suspicion of pseudomembranous colitis,  should be discontinued immediately and symptomatic treatment of conduct (eg., Oral vancomycin).In this state, drugs that inhibit peristalsis are contraindicated. bikini bodybuilder test 400 steroid bodybuilding trainer

5936

primobolan depot

Precautions levofloxacin should be used in patients with renal insufficiency; with a deficiency of glucose-6-phosphate dehydrogenase (increased risk of hemolytic anemia); diabetes; with psychosis and other mental disorders in history; with known risk factors for primobolan depot prolongation (congenital syndrome  interval, concomitant use of drugs that can prolong the interval  (eg, antiarrhythmics IA and III classes, tricyclic antidepressants, macrolides, antipsychotics), elderly patients and women may be more sensitive to the drugs , lengthens the interval ); with uncorrected electrolyte disturbances (eg, hypomagnesemia, hypokalemia, hyponatremia); elderly patients; Patients with cardiac disease (eg, heart failure, myocardial infarction, bradycardia); with a predisposition to convulsive reactions (cerebral atherosclerosis, cerebrovascular accidents (in history), organic diseases of the central nervous system); hepatic porphyria; while taking drugs that reduce the seizure threshold of the brain readiness (fenbufen and other similar non-steroidal anti-inflammatory, theophylline); while taking drugs that affect the tubular secretion (such as probenecid and cimetidine).

Application of pregnancy and during breastfeeding

During pregnancy, use of the drug Fleksid ® is contraindicated.
It is not known whether levofloxacin passes into breast milk, therefore, due to the possible risk of damage to the cartilage of the growing organism tissue during treatment with the drug should decide the issue of termination of breastfeeding.

Dosing and Administration

Inside.
Tablets primobolan depot should be taken once or twice a day, regardless of meals, without chewing and drinking plenty of fluids.
Can also be used for continuation of therapy in those patients who showed improvement under the initial / primary treatment levofloxacin appointed intravenously; Considering bioequivalence parenteral and oral forms of the drug can be used drug in the same dose.
The drug should be taken at least 2 hours before or 2 hours after ingestion of antacids containing magnesium and / or aluminum, iron salts, zinc salts, sucralfate or didanosine (ddI only those preparations, which contain as excipients magnesium and aluminum).
dose and duration of treatment depends on the indications for use and severity of the disease.

 

Side effect

According to the World adverse reactions are classified according to their rate of development as follows: ; the frequency is unknown – according to available data to set the frequency of occurrence is not possible. On the part of the gastrointestinal tract (GIT) common: nausea, diarrhea, vomiting uncommon: abdominal pain, dyspepsia, flatulence, constipation, frequency is not known: diarrhea mixed with blood, which in very rare cases, it may be a symptom of enterocolitis, including pseudomembranous colitis, pancreatitis, stomatitis. On the part of the liver and biliary tract common: increased activity of “liver” transaminases, increased alkaline phosphatase  and gamma-glutamyl transferase ; uncommon: increasing the concentration of bilirubin in the blood plasma, the frequency is not known: severe hepatic impairment, including cases of acute liver failure, sometimes fatal primarily in patients with severe underlying disease (eg, patients with sepsis), hepatitis, jaundice. The nervous system is often : headache, dizziness, insomniauncommon: vertigo, drowsiness, irritability, confusion, anxiety, tremor, anxiety; rare: “nightmarish” dream, paraesthesia, convulsions, depression, agitation, disorientation, psychotic reactions (eg, hallucinations, paranoia); the frequency is unknown: extrapyramidal disorders, and other disorders of coordination, dyskinesia, peripheral sensory neuropathy, peripheral sensory motor neuropathy, disturbance of the mind in violation of the behavior of self-harm, suicidal thoughts, suicide attempts, syncope, benign intracranial hypertension. from the side of feelings rare: dysgeusia (impaired taste sensitivity); rare:blurred vision (disturbance of visual perception), “ringing” in the ears of the frequency is not known: transient loss of vision, hearing loss (including hearing loss), parosmiya (impaired sense of smell), including anosmia (loss of smell), ageusia (loss of taste sensitivity).

On the part of the cardiovascular system rare: sinus tachycardia, decreased blood pressure, increased heart rate, the frequency is unknown:lengthening , ventricular arrhythmias and ventricular tachycardia type “pirouette» (torsades de pointes) predominantly in patients with risk factors for primobolan depot prolongation, ventricular tachycardia, which can lead to heart failure. On the part of the musculoskeletal system rarely: arthralgia, myalgia; rare: tendinitis, muscle weakness (of particular importance for patients with myasthenia), the frequency is not known: rhabdomyolysis, tendon rupture (eg Achilles tendon), ligament tear, muscle rupture, arthritis.

From the urinary system uncommon: hypercreatininemia; rare: acute renal failure (eg, due to . the development of interstitial nephritis) The respiratory system rare: shortness of breath; the frequency is not known: bronchospasm, hypersensitivity pneumonitis. skin and soft tissue uncommon: pruritus, rash, urticaria, rash, the frequency is not known: Stevens-Johnson syndrome, toxic epidermal necrolysis ( Lyell’s syndrome), exudative erythema multiforme, leykotsitoplastichesky vasculitis, photosensitivity reactions. immune system rare: angioneurotic edema, hypersensitivity reactions, the frequency is unknown: . anaphylactoid shock, anaphylactic shock, the part of the blood and lymphatic systemuncommon: eosinophilia, leukopenia, rarely neutropenia , thrombocytopenia, and the frequency is unknown: . hemolytic anemia, agranulocytosis, pancytopenia On the part of metabolism and nutritioninfrequent: anorexia rare: hypoglycemia (increased appetite, increased sweating, tremors, especially in patients with diabetes); very rarely attacks of porphyria (a very . rare metabolic disease) in patients who are already suffering from the disease, as evidenced by the experience of other quinolones This effect is not excluded the primobolan depot application of levofloxacin. frequency unknown: . hyperglycemia (increased blood glucose), hypoglycemic coma other rare: asthenia, fungal infection, superinfection; rare: pyrexia (fever), the frequency is not known: pain (including pain in back, chest, and extremities).

5938

methenolone

Levofloxacin is an antibacterial drug of broad-spectrum bactericidal action, blocks of methenolone – gyrase and topoisomerase  of, inhibits the synthesis . The following is a summary of data on the activity of levofloxacin on the basis of studies in vitro and clinical findings.

Sensitive bacteria (minimum inhibitory concentration (MIC) ≤2 mg / ml) Aerobic gram-positive microorganisms: Corynebacterium diphtheriae, Enterococcus faecalis, Enterococcus spp, Listeria monocytogenes, Staphylococcus coagulase-negative methi-S (I). (methicillin-susceptible coagulase / -umerenno sensitive), Staphylococcus aureus methi-S(metitsillin- sensitive), of Staphylococcus epidermidis methi, the S (methicillin-sensitive), Streptococci group C and G, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Viridans streptococci. Aerobic gram-negative microorganisms: of Acinetobacter baumannii, of Acinetobacter spp,.Actinobacillus actinomycetemcomitans, Citrobacter freundii, Eikenella corrodens, Enterobacter spp., Escherichia coli, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus parainfluenzae, Helicobacter pylori, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella spp., Moraxella catarrhalis, Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella spp, Proteus mirabilis, Proteus vulgaris, Providencia . spp, Pseudomonas methenolone aeruginosa (nosocomial infections caused by Pseudomonas aeruginosa, can require the combined treatment), Pseudomonas spp,. Salmonella spp,. Serratia marcescens, Serratia spp. Anaerobic microorganisms: Bacteroides fragilis, Bifidobacterium spp,. Fusobacterium spp,. of Propionibacterium spp,.Veilonella spp,. of Gardnerella vaginalis. Other micro-organisms: Bartonella spp,. of Chlamydophila pneumoniae, of Chlamydia psittaci, of Chlamydia trachomatis, of Legionella pneumophila, of Legionellaspp,. of Mycobacterium spp,. of Mycobacterium leprae, Micobacterium tuberculosis, of Mycoplasma pneumoniae, of Rickettsia spp. , . of Ureaplasma urealyticum moderately sensitive micro-organisms  Aerobic gram-positive microorganisms: of Corynebacterium urealiticum, of Corynebacterium xerosis, of Enterococcus faecium, of Staphylococcus epidermidis methi, the R (methicillin-resistant), Staphylococcus haemolyticus methi-R. Aerobic gram-negative microorganisms: Burkholderia . cepacia, Campilobacter jejuni / coli Anaerobic microorganisms: Bacteroides thetaiotaomicron, Bacteroides vulgatus, Bacteroides ovatus, Prevotella spp,. Porphyromonas spp,. Peptostreptococcus, Clostridium perfringens.

Stable levofloxacin microorganisms  Aerobic gram-positive microorganisms: Corynebacterium jeikeium , Staphylococcus aureus methi-R, Staphylococcus coagulase-negative methi-R. Aerobic gram-negative microorganisms: of Alcaligenes xylosoxidans, Burkholderia cepacia. Anaerobic microorganisms: of Bacteroides thetaiotaomicron, of Bacteroides fragilis. Other micro-organisms: . of Mycobacterium avium, of Mycoplasma hominis resistance resistance to levofloxacin occurs as a result phase process gene mutations encoding both types of topoisomerase II: DNA gyrase and topoisomerase IV (modification steps of the target). Other resistance mechanisms such as the mechanism of the effect on a penetration barriers microbial cells (mechanism characteristic of Pseudomonas aeruginosa) and efflux mechanism (active excretion of the antimicrobial agent from the microbial cells) may also reduce the sensitivity of microorganisms to levofloxacin. Between levofloxacin and other fluoroquinolone observed cross-resistance . in connection with the mechanism of action, cross resistance between levofloxacin and other groups antibacterial agents usually does not happen. The clinical effectiveness (efficacy in clinical trials for the treatment of infections caused listed below microorganisms) Aerobic gram-positive bacteria: Enterococcus faecalis, Staphylococcus aureus, Streptococcus . pneumoniae, Streptococcus pyogenes Aerobic gram-negative microorganisms: Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens. Others: Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae.

When administered levofloxacin is rapidly and almost completely absorbed from the gastrointestinal tract, bioavailability is approximately 99-100%. Maximum plasma concentrations are reached within 1-2 hours. food intake has almost no effect on the absorption of levofloxacin. Distribution Relationship to plasma proteins is 30-40%. After a single dose of 500 mg of levofloxacin is levofloxacin distribution volume is about 100 liters, indicating good drug penetration in human organs and tissues. The equilibrium concentration is reached within 48 h after administration of levofloxacin in a dose of 500 mg of 1 or 2 times per day. When administered 500 mg of levofloxacin: maximum concentration in bronchial mucosa and bronchial secretions are achieved after approximately 1 hour after drug administration and up 8.3 g / g and 10.8 micrograms / ml, respectively;maximum concentration achieved in lung tissue after 4-6 hours after dosing and approximately 11.3 ug / g. The concentration of drug in the lungs is greater than the concentration in the blood plasma.Levofloxacin penetrates poorly into cerebrospinal fluid. Metabolism Levofloxacin metabolized in small quantities to form the desmethyl-levofloxacin and levofloxacin-N-oxide. The share of these metabolites account for less than 5% of the dose excreted through the kidneys.  Elimination of the drug is mainly carried out by the kidneys (more than 85% of the dose).

 

Indications

Infections caused by methenolone enanthate susceptible to levofloxacin strains of microorganisms:
• upper respiratory tract infections (acute sinusitis);
• lower respiratory tract infections (acute exacerbations of chronic bronchitis, community-acquired pneumonia);
• urinary tract infection;
• chronic bacterial prostatitis;
• Skin and soft tissue infections;
• in the complex therapy of drug-resistant forms of tuberculosis.

5939

primobolan dosage

Reduces the effectiveness of uricosuric drugs, increases the effects of anticoagulants, antiplatelet agents, fibrinolytic agents, ethanol, and the side effects of glucocorticosteroids mineralokortikosteroidov, estrogen; reduces the effectiveness of antihypertensive drugs and diuretics.
The joint reception with others. Primobolan dosage, corticosteroids, ethanol, corticotropin may lead to ulceration and the development of gastro-intestinal bleeding, an increase in the risk of impairment of renal function.
Co-administration with oral anticoagulants, heparin, thrombolytics, antiplatelet, cefoperazone, cefamandole and tsefotetanom increases the risk of bleeding.
It increases the hypoglycemic effect of insulin and oral hypoglycemic drugs (requires recalculation of the dose).
Inductors microsomal oxidation in the liver (phenytoin, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase the production of hydroxylated active metabolites.
Co-administration with sodium valproate causes a disturbance of platelet aggregation.
Increases plasma concentration of nifedipine and verapamil, lithium, drugs, methotrexate.
antacids and cholestyramine reduce the absorption.
Myelotoxic drugs increase the expression gematotoksichnosti drug.
pharmaceutical incompatible with a solution of tramadol.

 

Special instructions:

With simultaneous use of ketoprofen and warfarin and coumarin anticoagulants or lithium salts patients should be under the strict supervision of a physician.
Caution should be exercised when administering the drug to patients with ulcerative diseases of the gastrointestinal tract in history, renal and hepatic insufficiency. During treatment necessary to monitor patterns of peripheral blood and functional state of the liver and kidneys. In violation of renal and hepatic function  need to decrease the dose and careful medical supervision.
If necessary, the definition of primobolan dosage steroids drug should be discontinued 48 hours before the test.
Avoid taking alcoholic drinks!
With the development of violations the organs of vision should consult an ophthalmologist.
In the period of treatment must be careful when driving vehicles and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.

 

Product form:

Valium for drug of a solution for intramuscular injection. At 100 mg drug in vials of dark glass type 1 with rings to be broken off.
A solution of benzyl primobolan dosage (solvent). 2.5 ml colorless glass vials of neutral glass of type 1 with rings to be broken off.
At 6 lyophilisate ampoules and vials with the solvent 6 for intramuscular administration of 2.5 ml, packed in a one or two plastic pallet, together with instructions for use in carton.

 

5942

primobolan side effects

In intramuscular a time to maximum plasma concentration is 15-30 minutes. Bioavailability – 90%. Associated primobolan side effects with the plasma protein by 99%. The equilibrium concentration in plasma is achieved at 24 hours after initiation of regular use. Therapeutic concentrations in the synovial fluid is maintained for 6-8 hours. It is metabolized in the liver by glyukuronirovaniya. It is shown mainly by the kidneys and intestines by 1-8%. The half-life is 1.6 – 1.9 hours, not accumulates..

 

Indications for use:

Short-term symptomatic treatment of acute pain in inflammatory processes of various origins: osteoarthritis, ankylosing spondylitis, gouty arthritis, acute gout, rheumatoid arthritis, psoriatic arthritis; bursitis, tenosynovitis; sciatica, myalgia, neuralgia, dorsalgia, sciatica; injuries and muscle strain; adnexitis, otitis media;headache and toothache; pain syndrome in oncology; post-traumatic and postoperative pain; algomenorrhea.

 

Contraindications:

 

  • individual hypersensitivity to ketoprofen, aspirin (including specifying a history of bronchospasm, urticaria or rhinitis caused by the intake of acetylsalicylic acid);
  • gastrointestinal disease in the acute phase;
  • gastrointestinal bleeding and perforation in history;
  • The expressed disturbances of function of kidneys and liver;
  • blood disorders (leucopenia, thrombocytopenia, blood coagulation disorders, hemophilia);
  • relief of pain immediately before or immediately after surgical treatment of cardiovascular system;
  • severe heart failure;
  • pregnancy and lactation;
  • children’s age (18 years).Precautions:
    Caution is advised to use the drug in patients: with impaired liver and / or kidney disease, gastrointestinal diseases in history; asthma, rhinitis, urticaria, polyps of the nasal mucosa; hypertension and / or cardiovascular disease, cerebrovascular disease; blood diseases, anemia; alcoholism, alcoholic liver cirrhosis, hyperbilirubinemia, diabetes, dehydration, smoking, sepsis, and in older patients. 

    Dosage and administration:

    The lyophilizate is dissolved attached solvent and the resulting solution was injected deep into the muscle. Intramuscular injection is indicated for the relief of acute pain, 100 mg 1-2 times a day. Duration of the parenteral treatment usually short-lived and is several days. After reaching the desired effect to the patient is prescribed capsules or suppositories.
    The maximum daily dose should not exceed 300 mg.

    Side effects:
    From the digestive system: primobolan side effects, abdominal pain, dyspepsia (nausea, vomiting, heartburn, flatulence, loss of appetite, diarrhea), stomatitis; change in taste, ulceration, and perforation of the mucous membrane of the gastrointestinal tract, gingival, gastrointestinal, hemorrhoidal bleeding; increased activity of “liver” transaminases serum hepatitis.
    Nervous system: headache, dizziness, insomnia, agitation, nervousness, somnolence, depression, fatigue, confusion or loss of consciousness, forgetfulness, migraines, peripheral neuropathy.
    From the senses : noise or ringing in the ears, blurred vision, conjunctivitis, mucosal dryness of the eye, eye pain, conjunctival hyperemia, hearing loss, vertigo.
    cardio-vascular system: increased blood pressure, tachycardia.
    From the side of hematopoiesis: rarely – agranulocytosis , anemia, hemolytic anemia, thrombocytopenia, leukopenia.
    From the urinary system: edema syndrome, cystitis, urethritis, renal failure, interstitial nephritis, nephrotic syndrome, hematuria.
    On the part of the respiratory system: dyspnea, bronchospasm, rhinitis, laryngeal edema, epistaxis , coughing up blood, shortness of breath.
    With the skin: alopecia, eczema, erythema multiforme exudative, including Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), fotodermatit.
    Allergic reactions: skin rash (including erythematous, urticaria), itching, angioedema, exfoliative dermatitis, anaphylactic shock.
    Other: increased primobolan side effects sweating, myalgia, muscle twitching, thirst, vaginal bleeding, pain and redness at the injection site.

     

    Overdose:

    Symptoms: may cause drowsiness, nausea, vomiting, abdominal pain, bleeding, liver dysfunction and kidneys.
    Treatment is symptomatic: There is no specific antidote.